Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis
BJUI Compass · 2023-05 · 4 (3) · 256-265
DOI: 10.1002/bco2.212 ↗At a glance
Übersichtsarbeit in BJUI Compass, published online on 2023-01-02. Written by Junru Chen and 6 co-authors. Institution: Department of Urology, Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan China. Cited 39 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Canadian Institutes of Health Research, National Natural Science Foundation of China, Terry Fox Research Institute.
Abstract (original language)
Background
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta‐analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular features to potentially inform precision medicine.
Methods
EMBASE, PubMed, and Cochrane Central Register of Controlled Trials databases were searched for eligible studies until March 2022. Study qualities were assessed using the Q‐genie tool. The prevalence of gene mutations and copy number alterations (CNAs) were extracted, and meta‐analysis was performed using R Studio with meta package.
Results
A total of 14 studies with 449 NEPC patients were included in this meta‐analysis. The most frequently mutated gene in NEPC was TP53 (49.8%), and the prevalence of deleterious mutations in ATM/BRCA was 16.8%. Common CNAs in NEPC included RB1 loss (58.3%), TP53 loss (42.8%), PTEN loss (37.0%), AURKA amplification (28.2%), and MYCN amplification (22.9%). RB1/TP53 alterations and concurrent RB1 and TP53 alterations were remarkably common in NEPC, with a prevalence of 83.8% and 43.9%, respectively. Comparative analyses indicated that the prevalence of (concurrent) RB1/TP53 alterations was significantly higher in de novo NEPC than in treatment‐emergent NEPC (t‐NEPC).
Conclusions
This study presents the comprehensive prevalence of common genomic alterations and potentially actionable targets in NEPC and reveals the genomic differences between de novo NEPC and t‐NEPC. Our findings highlight the importance of genomic testing in patients for precision medicine and provide insights into future studies exploring different NEPC subtypes.
Subjects
Author keywords
Authors and institutions
- Department of Urology, Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan China.
- Vancouver Prostate Centre Vancouver BC Canada.
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada.
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada.
ORCID profiles: Hao Zeng, Yuzhuo Wang
Funding
- Canadian Institutes of Health Research
- National Natural Science Foundation of China
- Terry Fox Research Institute
- Sichuan University
Cite
APA
Chen, J., Shi, M., Chuen Choi, S. Y., Wang, Y., Lin, D., Zeng, H., & Wang, Y. (2023). Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis. BJUI Compass, 4(3), 256-265. https://doi.org/10.1002/bco2.212
Vancouver
Chen J, Shi M, Chuen Choi SY, Wang Y, Lin D, Zeng H, et al. Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis. BJUI Compass. 2023;4(3):256-265. doi:10.1002/bco2.212
BibTeX
@article{Chen2023,
author = {Chen, Junru and Shi, Mingchen and Chuen Choi, Stephen Yiu and Wang, Yu and Lin, Dong and Zeng, Hao and Wang, Yuzhuo},
title = {Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis},
journal = {BJUI Compass},
year = {2023},
volume = {4},
number = {3},
pages = {256--265},
doi = {10.1002/bco2.212}
}
EUVIMED